Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Nasalfent begins phase III program in breakthrough cancer pain

Jan. 31, 2007

Recent Allergan and Florida Atlantic University patents divulge novel analgesic agents

Jan. 30, 2007

T-0047 clinical testing resumes

Jan. 30, 2007

Japanese approval for Modiodal in narcolepsy

Jan. 30, 2007

Valeant develops intranasal diazepam for seizure emergencies

Jan. 30, 2007

Michael J. Fox Foundation funds industry development efforts in Parkinson's

Jan. 30, 2007

Antiparkinsonian effects of S-32504 via D2 receptors are not associated with significant dyskinesia

Jan. 29, 2007

Preclinical characterization of SLV-313, a novel D2 receptor antagonist/5-HT1A receptor agonist

Jan. 29, 2007

Barrow receives grant to support neurofibromatosis research

Jan. 26, 2007

New trial evaluates oral cladribine with Rebif for MS

Jan. 26, 2007

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...